Skip to main content

Advertisement

Table 3 Univariate analyses (logrank test)

From: Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study

  n 10-yr. OS (%) %95 CI (%) p-value 10-yr. DFS (%) %95 CI (%) p-value 10-yr. LC (%) %95 CI (%) p-value 10-yr. MM (%) %95 CI (%) p-value
All patients 206 52 43–61   25 15–35   79 69–89   72 62–82  
Age (year)
   ≤ 60 103 63 50–76 <0.0001 29 16–42 0.02 79 64–94 0.46 67 53–81 0.007
   >60 03 34 19–49   22 9–35   79 67–91   76 62–90  
Gender
   Female 73 52 36–68 0.98 38 23–53 0.79 88 79–97 0.60 58 43–73 0.77
   Male 133 49 37–61   23 13–33   75 62–88   74 63–85  
Site of plasmacytoma
   Vertebra 102 52 38–66 0.99 19 4–34 0.89 89 79–98 0.07 79 64–94 0.39
   Other 104 48 35–61   28 16–40   78 68–88   66 53–79  
Largest tumor dimension (cm)
   <5 45 67 36–98 0.001 24 7–41 0.73 87 75–99 0.47 79 58–100 0.31
   ≥ 5 59 57 42–72   34 19–49   78 65–91   58 42–74  
   NA 102 33 19–47   16 0–33   73 50–96   80 64–96  
IgM subtype
   Kappa 59 49 19–47 0.57 0 - 0.57 60 24–94 0.49 91 75–100 0.36
   Lambda 100 31 61 40–81   35 16–54   87 69–100   65 46–84  
   NA 116 49 37–61   22 20–44   84 75–93   64 52–76  
Type of treatment
   RT alone 169 51 40–62 0.49 27 16–38 0.92 78 66–90 0.27 71 60–82 0.93
   CT + RT 100 32 43 20–66   15 0–39   93 84-   77 54–100  
2 Gy/fr equivalent RT dose (Gy) a
   ≥ 50 56 47 28–66 0.50 26 10–42 0.06 82 68–96 <0.0001b 71 55–87 0.25
   ≥ 40 and <50 65 55 34–76   25 6–44   67 40–94   78 59–97  
   ≥ 30 and <40 55 46 28–64   32 16–48   90 81–99   63 47–79  
   <30 25 37 13–61   17 0–43   96 88–100   81 53–100  
   No RTc 5 0 -   0 -   0 -   33 0–86  
  1. OS: overall survival; CI: confidence interval; DFS: disease-free survival; LC: local control; MM: progression to multiple myeloma; NA: not available; CT: chemotherapy; RT: radiation therapy abiologically effective dose (BED) according to the linear-quadratic model.13 BED = nd(1+ [d÷α/β]) where n = number of fractions, d = dose per fraction, and α/β = 10 for plasmacytoma. bnot significant when excluding patients not receiving radiation therapy. cAll patients treated with surgery alone (with chemotherapy in one).